Geneprodx

What Geneprodx does

GeneproDX is a Chilean-based precision medicine company founded in 2015 that has developed ThyroidPrint®, a molecular diagnostic test designed to reclassify indeterminate thyroid nodules (Bethesda III/IV) as benign or suspicious for malignancy. The test analyzes 10 genetic markers via real-time PCR and applies a proprietary neural network-based algorithm, delivering results in approximately 3 hours with reported performance metrics of 91% sensitivity, 88% specificity, and 95% negative predictive value. The company is led by founder and CEO Dr. Hernan González (MD, PhD), whose research at the Pontificia Universidad Católica de Chile forms the scientific basis for the assay, and the technology is protected by patents granted in nine major jurisdictions including the U.S., EU, China, and Japan.

GeneproDX distributes ThyroidPrint® through a hybrid model: a decentralized channel running on Biocartis's Idylla™ platform, which is installed in 88+ countries and enables in-hospital testing with a 3-hour turnaround, and a centralized CAP-accredited laboratory service that resumed in mid-2022 after a temporary COVID-19 testing pivot. The target customer base spans physicians (endocrinologists, surgeons), hospitals, and healthcare systems across Latin America and Europe, with 300+ physicians and 1,200+ patients reported to date across 8 commercially active countries. Strategic expansion into the U.S., Asia, the Middle East, Canada, and Oceania is planned through 2026.

The business model combines per-test diagnostic revenue with what appear to be subscription/enterprise licensing tiers ($279/year starter, $449/year enterprise) for platform access, supplemented by centralized lab service fees. To date, the company has raised approximately $6.2M across disclosed rounds (2017 and 2021), with strategic investment from Biocartis Group NV, and operates with 11-50 employees from headquarters in Santiago, Chile and a European office in Barcelona, Spain.

Name

Geneprodx

Legal name

GENEPRODX CHILE SPA

Website

https://geneprodx.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

GeneproDX is a Chilean precision medicine company commercializing ThyroidPrint®, a neural-network-driven molecular diagnostic that reclassifies indeterminate thyroid nodules to reduce unnecessary surgeries. It serves hospitals and physicians across 8 countries via Biocartis's Idylla™ platform and a CAP-accredited lab.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Thyroid Disorders (HLAKADAF)

Keywords

• Molecular diagnostics
• Thyroid cancer testing
• Precision medicine
• Genetic biomarker analysis
• Clinical diagnostics

Headquarters

HQ city

Santiago

HQ country

Chile

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. ThyroidPrint® Diagnostic Testing: Revenue generated from molecular diagnostic tests for indeterminate thyroid nodules. Tests can be performed either at hospitals using the Idylla™ platform (decentralized model) or through centralized laboratory service. Pricing tiers (Starter $279/year, Enterprise $449/year) suggest a subscription or licensing model for platform access.
2. Laboratory Services: Centralized testing service resumed as of mid-2022 for ThyroidPrint® test. Samples analyzed in state-of-the-art laboratory facilities.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

GeneproDX provides ThyroidPrint, a molecular diagnostic test that analyzes 10 genetic markers via real-time PCR and a neural network-based algorithm to predict whether indeterminate (Bethesda III/IV) thyroid nodules are benign, returning results in approximately 3 hours. The test is delivered either on-site at hospitals running the Biocartis Idylla platform or through GeneproDX's CAP-accredited centralized laboratory, and is intended for use by endocrinologists, surgeons, hospitals and patients to avoid unnecessary thyroid surgery.

Product overview

GeneproDX offers a single core product—ThyroidPrint®—a molecular diagnostic test for thyroid cancer detection. The company combines genomics and artificial intelligence on the Biocartis Idylla™ platform to deliver cutting-edge tests for clinical consultations. ThyroidPrint® analyzes genetic markers from thyroid nodule samples to classify indeterminate nodules as benign or suspicious, ensuring accurate diagnosis and prevention of unnecessary surgeries. The test can be performed either directly in hospitals equipped with the Idylla™ platform (decentralized model) or through GeneproDX's centralized laboratory service.

Differentiator

Problem solved

Functional benefit

Brands

• ThyroidPrint: Molecular diagnostic test for indeterminate thyroid nodules that predicts benignity using 10 genetic markers and real-time PCR technology

Products and services

• ThyroidPrint® Molecular Diagnostic Test Molecular diagnostic test that analyzes 10 genetic markers via real-time PCR and a neural network-based algorithm to predict benignity of indeterminate thyroid nodules (Bethesda III/IV). Returns results in approximately 3 hours with 91% sensitivity, 88% specificity, and 95% NPV, intended for endocrinologists, endocrine surgeons, hospitals and laboratories to avoid unnecessary thyroid surgery.
• ThyroidPrint® Decentralized Hospital Testing (via Biocartis Idylla™) Hospital-based delivery of the ThyroidPrint test on the Biocartis Idylla platform, allowing hospitals and laboratories to run the test on-site with a 3-hour turnaround time. Available in 88+ countries where the Idylla platform is installed.
• ThyroidPrint® Centralized Laboratory Service Centralized laboratory testing service where thyroid nodule samples are sent to GeneproDX's CAP-accredited laboratory (CAP No. 1821095) for ThyroidPrint analysis. Provides an alternative delivery channel for hospitals and physicians without on-site Idylla platform access.

Quantifiable outcome

• Over 95% diagnostic accuracy
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• BiocartiscoreTechnology or IntegrationStrategic partnership with Biocartis enables ThyroidPrint® to run on the Idylla™ platform, making it the world's only decentralized molecular test for thyroid nodules. This partnership allows hospitals in 88+ countries to perform ThyroidPrint® testing directly on-site with 3-hour turnaround time.
• Pontificia Universidad Católica de ChilecoreStrategic or Co-development PartnerResearch partnership for development of ThyroidPrint® technology. Originated from Dr. Hernan Gonzalez's research group at the Oncology Laboratory of the Faculty of Medicine. Published clinical validation studies (Thyroid 2017) with 1,300 patient cohort.

Scale indicators12 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Veracyte: Veracyte markets the Afirma Genomic Sequencing Classifier, the most established molecular test for indeterminate thyroid nodules in the U.S., and is the most direct competitive counterpart to ThyroidPrint® in the same indication and customer segment (endocrinologists and surgeons).
• Interpace Diagnostics: Interpace offers ThyGeNEXT and ThyraMIR for thyroid nodule risk stratification, directly overlapping GeneproDX's indeterminate thyroid nodule molecular testing positioning and target physician specialties.
• Sonic Healthcare (ThyroSeq): ThyroSeq, now commercialized via Sonic Healthcare, is a DNA/RNA NGS-based molecular test for indeterminate thyroid nodules — the closest functional comparable to ThyroidPrint® among marketed competitors.

Broad incumbents

• QIAGEN: QIAGEN is a global molecular diagnostics leader with sample-to-insight workflows (including the therascreen franchise) that overlap with the PCR-based, biomarker-driven approach GeneproDX uses for thyroid nodules.
• Cepheid (Danaher): Cepheid's GeneXpert is the leading decentralized molecular diagnostics platform and competes architecturally with the Idylla™ platform on which ThyroidPrint® runs.
• Quest Diagnostics: Quest provides centralized thyroid cancer and molecular testing services across the U.S. and competes with GeneproDX's centralized lab offering for indeterminate thyroid nodule cases.
• Laboratory Corporation of America (LabCorp): LabCorp is a large reference lab offering thyroid pathology and molecular oncology services, overlapping with GeneproDX's centralized ThyroidPrint® service model.
• NeoGenomics: NeoGenomics provides oncology-focused molecular and genetic testing services, with broad overlap in biomarker-driven cancer diagnostics similar to GeneproDX's AI-driven approach.
• Hologic: Hologic's molecular diagnostics franchise (e.g., Panther system) targets decentralized nucleic acid testing and competes indirectly with the Idylla™-based decentralized model GeneproDX relies on.

Others

• Biocartis: Biocartis is GeneproDX's strategic technology partner and an investor; the Idylla™ platform is the foundation for ThyroidPrint's decentralized footprint, making Biocartis both a critical enabler and a stakeholder.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/40805942/admin/feed/posts

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geneprodx